Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Tax Provisions (2020 - 2025)

Bioventus (BVS) has disclosed Tax Provisions for 6 consecutive years, with -$3.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Tax Provisions fell 677.27% year-over-year to -$3.2 million, compared with a TTM value of -$1.6 million through Dec 2025, up 70.43%, and an annual FY2025 reading of -$1.6 million, up 70.43% over the prior year.
  • Tax Provisions was -$3.2 million for Q4 2025 at Bioventus, down from $664000.0 in the prior quarter.
  • Across five years, Tax Provisions topped out at $1.7 million in Q3 2021 and bottomed at -$29.5 million in Q4 2022.
  • Average Tax Provisions over 5 years is -$3.1 million, with a median of -$95000.0 recorded in 2025.
  • The sharpest move saw Tax Provisions surged 1658.18% in 2021, then plummeted 6930.14% in 2022.
  • Year by year, Tax Provisions stood at -$2.7 million in 2021, then tumbled by 302.31% to -$11.0 million in 2022, then soared by 98.67% to -$146000.0 in 2023, then soared by 476.71% to $550000.0 in 2024, then crashed by 677.27% to -$3.2 million in 2025.
  • Business Quant data shows Tax Provisions for BVS at -$3.2 million in Q4 2025, $664000.0 in Q3 2025, and $1.0 million in Q2 2025.